Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation

▤ Summary

Goldenrod Therapeutics closed the initial tranche of a $6.5 million Series Seed round to advance its brain inflammation program. The company will use the money for manufacturing, formulation work, IND-enabling studies, and a Phase I trial in Friedreich’s Ataxia. Goldenrod says its lead candidate, 11h, is a brain-penetrant PDE4 inhibitor designed to overcome limitations of earlier drugs in this class. The company also plans to use early human data to support development across several neurodegenerative and neuroinflammatory indications. Goldenrod expects to begin clinical development in 2027.

$ Funding

▦ Linked Companies